Table 1.
Correlation between levels of DEPTOR and clinicopathological parameters for pre-CRT samples
| Variables | No. patients (%) | DEPTOR levels |
Hazard ratio (95% CI) | p | |
|---|---|---|---|---|---|
| Low (n, %) | High (n, %) | ||||
| Gender | 0.065 | ||||
| Male | 59 (93.7) | 28 (44.4) | 31 (49.2) | 1.129 (1.002–1.272) | |
| Female | 4 (6.4) | 0 | 4 (6.35) | – | |
| Age, ya | 0.176 | ||||
| ≤58 | 33 (52.4) | 12 (19.0) | 21 (33.3) | 0.714(0.431–1.185) | |
| >58 | 30 (47.6) | 16 (25.4) | 14 (22.2) | 1.429(0.852–2.396) | |
| Smoke | 0.575 | ||||
| No | 18 (28.6) | 7 (11.1) | 11 (17.5) | 0.795(0.355–1.783) | |
| Yes | 45 (71.4) | 21 (33.3) | 24 (38.1) | 1.094(0.802–1.491) | |
| Drink | 0.344 | ||||
| No | 22 (34.9) | 8 (12.7) | 14 (22.2) | 0.714(0.350–1.456) | |
| Yes | 41 (65.1) | 20 (31.7) | 21 (33.3) | 1.190(0.832–1.703) | |
| cT | 0.374 | ||||
| I-II | 17 (27.0) | 6 (9.5) | 11 (17.5) | 0.682 (0.288–1.614) | |
| III-IV | 46 (73.0) | 22 (34.9) | 24 (38.1) | 1.146 (0.852–1.541) | |
| cN | 0.948 | ||||
| 0–1 | 16 (25.4) | 7 (11.1) | 9 (14.3) | 0.972 (0.414–2.283) | |
| 2–3 | 47 (74.6) | 21 (33.3) | 26 (41.3) | 1.010 (0.756–1.348) | |
| cTNM | 0.575 | ||||
| II-III | 18 (28.6) | 9 (14.3) | 9 (14.3) | 1.250 (0.574–2.724) | |
| IVA-IVB | 45 (71.4) | 19 (30.2) | 26 (41.3) | 0.913 (0.663–1.259) | |
| Pathologic grade | 0.441 | ||||
| Low/intermediate | 23 (46.0) | 11 (22.0) | 12 (24.0) | 1.266 (0.698–2.295) | |
| High | 27 (54.0) | 10 (20.0) | 17 (34.0) | 0.812 (0.472–1.398) | |
| Induced chemotherapy | 0.419 | ||||
| No | 4 (6.3) | 1 (1.6) | 3 (5.0) | 0.417 (0.046–3.790) | |
| Yes | 59 (93.7) | 27 (42.9) | 32 (50.8) | 1.055 (0.932–1.194) | |
| Induced chemotherapy regimens | 0.239 | ||||
| TPF | 25 (42.4) | 11 (18.6) | 14 (23.7) | – | |
| TP | 19 (32.2) | 6 (10.2) | 13 (22.0) | – | |
| PF | 12 (20.3) | 8 (13.6) | 4 (6.8) | – | |
| TPF/TP + PDL1 | 3 (5.1) | 2 (3.4) | 1 (1.7) | – | |
| Concurrent chemotherapy | 0.565 | ||||
| No | 6 (9.5) | 2 (3.2) | 4 (6.3) | 0.625 (0.123–3.168) | |
| Yes | 57 (90.5) | 26 (41.3) | 31 (49.2) | 1.048 (0.896–1.227) | |
| Tumor size, cm | 0.006 | ||||
| ≤2 | 17 (27.0) | 5 (7.9) | 12 (19.0) | – | |
| >2–≤4 | 31 (49.2) | 11 (17.5) | 20 (31.7) | – | |
| >4 | 15 (23.8) | 12 (19.0) | 3 (4.8) | – | |
| RECIST | 0.002 | ||||
| CR/PR | 31 (51.7) | 8 (13.3) | 23 (38.3) | 0.425 (0.228–0.793) | |
| SD/PD | 29 (48.3) | 19 (31.7) | 10 (16.7) | 2.322 (1.310–4.116) | |
| p-S6 | <0.001 | ||||
| IRS<8 | 32 (50.8) | 5 (7.9) | 27 (42.9) | 0.231 (0.103–0.523) | |
| IRS≥8 | 31 (49.2) | 23 (36.5) | 8 (22.9) | 3.594 (1.909–6.766) | |
| Status | 0.002 | ||||
| Alive | 44 (69.8) | 14 (22.2) | 30 (47.6) | 0.583 (0.393–0.865) | |
| Dead | 19 (30.2) | 14 (22.2) | 5 (7.9) | 3.500 (1.434–8.540) | |
Boldface values are statistically significant.
a
Median; cT: clinical T stage; cN: clinical N stage.